• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用大环表位开发针对新冠病毒S蛋白的优质抗体。

Development of superior antibodies against the S-protein of SARS-Cov-2 using macrocyclic epitopes.

作者信息

Traboulsi Hassan, Khedr Mohammed A, Elgorashe Rafea, Al-Faiyz Yasair, Negm Amr

机构信息

Department of Chemistry, College of Science, King Faisal University, P.O Box 400, Al-Ahsa 31982, Saudi Arabia.

Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-AHasa 31982, Saudi Arabia.

出版信息

Arab J Chem. 2022 Mar;15(3):103631. doi: 10.1016/j.arabjc.2021.103631. Epub 2021 Dec 10.

DOI:10.1016/j.arabjc.2021.103631
PMID:34909055
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8662835/
Abstract

One of the proven methods to prevent and inhibit viral infections is to use antibodies to block the initial Receptor Binding Domain (RBD) of SARS-CoV-2 S protein and avoid its binding with the host cells. Thus, developing these RBD-targeting antibodies would be a promising approach for treating the SARS-CoV-2 infectious disease and stop virus replication. Macrocyclic epitopes constitute closer mimics of the receptor's actual topology and, as such, are expected to be superior epitopes for antibody generation. This work demonstrated the vital effect of the three-dimensional shape of epitopes on the developed antibodies' activity against RBD protein of SARS-CoV-2. The molecular dynamics studies showed the greater stability of the cyclic epitopes in comparison with the linear counterpart, which was reflected in the activity of their produced antibodies. Indeed, the antibodies we developed using macrocyclic epitopes showed superiority with respect to binding to RBD proteins compared to antibodies formed from a linear peptide. The results of the present work constitute a roadmap for developing superior antibodies that could be used to inhibit the activity of the SARS-CoV-2 and prevent its reproduction.

摘要

预防和抑制病毒感染的一种已被证实的方法是使用抗体来阻断严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白的初始受体结合域(RBD),并避免其与宿主细胞结合。因此,开发这些靶向RBD的抗体将是治疗SARS-CoV-2传染病和阻止病毒复制的一种有前景的方法。大环表位更接近受体的实际拓扑结构,因此有望成为产生抗体的优质表位。这项工作证明了表位的三维形状对所开发的针对SARS-CoV-2 RBD蛋白的抗体活性的重要影响。分子动力学研究表明,与线性表位相比,环状表位具有更高的稳定性,这反映在它们所产生抗体的活性上。事实上,与由线性肽形成的抗体相比,我们使用大环表位开发的抗体在与RBD蛋白结合方面表现出优越性。本研究结果为开发可用于抑制SARS-CoV-2活性并防止其繁殖的优质抗体提供了路线图。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3342/8662835/77470e349d36/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3342/8662835/e976f2d94852/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3342/8662835/d7ec5916134c/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3342/8662835/d835fc6a7177/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3342/8662835/ebadb19a9347/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3342/8662835/77470e349d36/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3342/8662835/e976f2d94852/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3342/8662835/d7ec5916134c/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3342/8662835/d835fc6a7177/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3342/8662835/ebadb19a9347/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3342/8662835/77470e349d36/gr5_lrg.jpg

相似文献

1
Development of superior antibodies against the S-protein of SARS-Cov-2 using macrocyclic epitopes.利用大环表位开发针对新冠病毒S蛋白的优质抗体。
Arab J Chem. 2022 Mar;15(3):103631. doi: 10.1016/j.arabjc.2021.103631. Epub 2021 Dec 10.
2
Structure-Based Epitope Design: Toward a Greater Antibody-SARS-CoV-2 RBD Affinity.基于结构的表位设计:迈向更高的抗体与新冠病毒刺突蛋白受体结合域亲和力
ACS Omega. 2021 Nov 18;6(47):31469-31476. doi: 10.1021/acsomega.1c03348. eCollection 2021 Nov 30.
3
Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.全面描述了针对 SARS-CoV-2 刺突蛋白的抗体反应,发现了除轻度感染诱导的表位之外的其他疫苗诱导的表位。
Elife. 2022 Jan 24;11:e73490. doi: 10.7554/eLife.73490.
4
Novel Regioselective Approach to Cyclize Phage-Displayed Peptides in Combination with Epitope-Directed Selection to Identify a Potent Neutralizing Macrocyclic Peptide for SARS-CoV-2.新型区域选择性环化噬菌体展示肽与表位导向选择相结合的方法,鉴定出针对 SARS-CoV-2 的有效中和大环肽。
ACS Chem Biol. 2022 Oct 21;17(10):2911-2922. doi: 10.1021/acschembio.2c00565. Epub 2022 Sep 29.
5
Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.人类针对 SARS-CoV-2 刺突蛋白受体结合域的中和抗体的结构基础。
Microbiol Spectr. 2021 Oct 31;9(2):e0135221. doi: 10.1128/Spectrum.01352-21. Epub 2021 Oct 13.
6
Neutralization of SARS-CoV-2 requires antibodies against conformational receptor-binding domain epitopes.中和 SARS-CoV-2 需要针对构象受体结合域表位的抗体。
Allergy. 2022 Jan;77(1):230-242. doi: 10.1111/all.15066. Epub 2021 Sep 22.
7
Monoclonal antibody designed for SARS-nCoV-2 spike protein of receptor binding domain on antigenic targeted epitopes for inhibition to prevent viral entry.针对 SARS-nCoV-2 刺突蛋白受体结合域的抗原靶向表位设计的单克隆抗体,用于抑制以防止病毒进入。
Mol Divers. 2023 Apr;27(2):695-708. doi: 10.1007/s11030-022-10449-x. Epub 2022 May 26.
8
Characterization of a neutralizing antibody that recognizes a loop region adjacent to the receptor-binding interface of the SARS-CoV-2 spike receptor-binding domain.鉴定一种中和抗体,该抗体识别 SARS-CoV-2 刺突受体结合结构域紧邻受体结合界面的环区。
Microbiol Spectr. 2024 Apr 2;12(4):e0365523. doi: 10.1128/spectrum.03655-23. Epub 2024 Feb 28.
9
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.通过 SARS-CoV-2 刺突蛋白变体逃避中和抗体。
Elife. 2020 Oct 28;9:e61312. doi: 10.7554/eLife.61312.
10
SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses.新冠病毒 Spike 蛋白在封闭状态下稳定诱导强烈的中和反应。
J Virol. 2021 Jul 12;95(15):e0020321. doi: 10.1128/JVI.00203-21.

本文引用的文献

1
ACE-2-Derived Biomimetic Peptides for the Inhibition of Spike Protein of SARS-CoV-2.用于抑制 SARS-CoV-2 刺突蛋白的 ACE2 衍生仿生肽。
J Proteome Res. 2021 Feb 5;20(2):1296-1303. doi: 10.1021/acs.jproteome.0c00686. Epub 2021 Jan 20.
2
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited.羟氯喹和阿奇霉素用于治疗新型冠状病毒肺炎:重新审视一项开放标签非随机临床试验的结果
Int J Antimicrob Agents. 2021 Jan;57(1):106243. doi: 10.1016/j.ijantimicag.2020.106243.
3
Coronavirus disease 2019 and the revival of passive immunization: Antibody therapy for inhibiting severe acute respiratory syndrome coronavirus 2 and preventing host cell infection: IUPHAR review: 31.
新型冠状病毒病 2019 与被动免疫的复兴:抑制严重急性呼吸综合征冠状病毒 2 和防止宿主细胞感染的抗体治疗:国际药理学联合会综述:31.
Br J Pharmacol. 2021 Sep;178(17):3359-3372. doi: 10.1111/bph.15359. Epub 2021 Apr 14.
4
Viral targets for vaccines against COVID-19.针对 COVID-19 的疫苗的病毒靶点。
Nat Rev Immunol. 2021 Feb;21(2):73-82. doi: 10.1038/s41577-020-00480-0. Epub 2020 Dec 18.
5
RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.基于 RBD-Fc 的 COVID-19 疫苗候选物诱导产生高滴度的 SARS-CoV-2 中和抗体反应。
Signal Transduct Target Ther. 2020 Nov 27;5(1):282. doi: 10.1038/s41392-020-00402-5.
6
Transmission Modes of COVID-19: A Systematic Review.新型冠状病毒肺炎的传播途径:系统综述。
Infect Disord Drug Targets. 2021;21(6):e170721187995. doi: 10.2174/1871526520666201116095934.
7
A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.《COVID-19 疫苗研发的进展与挑战综述》。
Front Immunol. 2020 Oct 14;11:585354. doi: 10.3389/fimmu.2020.585354. eCollection 2020.
8
Generation of Chicken IgY against SARS-COV-2 Spike Protein and Epitope Mapping.针对 SARS-CoV-2 刺突蛋白的鸡 IgY 的产生和表位作图。
J Immunol Res. 2020 Oct 17;2020:9465398. doi: 10.1155/2020/9465398. eCollection 2020.
9
A systematic review of SARS-CoV-2 vaccine candidates.SARS-CoV-2 疫苗候选物的系统评价。
Signal Transduct Target Ther. 2020 Oct 13;5(1):237. doi: 10.1038/s41392-020-00352-y.
10
The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series.新冠肺炎患者恢复期血浆疗法的疗效评估:一项多中心病例系列研究。
Signal Transduct Target Ther. 2020 Oct 6;5(1):219. doi: 10.1038/s41392-020-00329-x.